From: Late term tolerance in head neck cancer patients irradiated in the IMRT era
Parameters | LRC, >12mo FU |
---|---|
N patients | 707 |
Gender (f: m) | 25%:75% |
Mean age (range) | 62 (39-91) years |
Mean/Median FU (range) | 41/35 (15-124) months |
Diagnosis | |
Unknown | 19 (3%) |
Central oropharynx | 96 (14%) |
Lateral oropharynx | 149 (21%) |
Hypopharynx | 69 (10%) |
Oral cavity | 111 (16%) |
Nasopharynx | 51 (7%) |
Larynx | 90 (13%) |
Sinonasal | 40 (5%) |
Parotid gland | 36 (5%) |
Skin | 33 (5%) |
Nasal | 10 (1%) |
Others | 3 (3%) |
Treatment (dose) | |
Primary IMRT (66-72 Gy, 2.0-2.2 Gy/f) | 55% (n=388) |
Postoperative IMRT (60-66 Gy, 2.0 Gy/f) | 45% (n=319) |
T | |
1 | 17% |
2 | 34% |
3 | 20% |
4 | 26% |
Unknown | 3% |
N stage | |
Recurrence | 2% |
NO | 32% |
N1-2b | 45% |
N2c | 17% |
N3 | 4% |
Total gross tumor volume (n=388) | |
Mean (range) | 62 cc (1-217) |
1-15 cc | 115 |
16-70 cc | 202 |
71-130 cc | 63 |
>130 cc | 8 |
Conc. systemic therapy | |
None | 15% |
Cisplatin only | 62% |
Cetuximab only | 16% |
Cisplatin switched to Cetuximab | 7% |
Induction chemotherapy | 3% |